Omeros Corp OMER:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/12/22 EDT
6.80quote price arrow down-0.33 (-4.63%)
Volume
4,005
Close
7.13quote price arrow down-0.07 (-0.97%)
Volume
640,794
52 week range
1.85 - 16.57
Loading...
  • Open7.24
  • Day High7.46
  • Day Low7.04
  • Prev Close7.20
  • 52 Week High16.57
  • 52 Week High Date09/01/21
  • 52 Week Low1.85
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap447.26M
  • Shares Out62.73M
  • 10 Day Average Volume0.84M
  • Dividend-
  • Dividend Yield-
  • Beta1.16
  • YTD % Change10.89

KEY STATS

  • Open7.24
  • Day High7.46
  • Day Low7.04
  • Prev Close7.20
  • 52 Week High16.57
  • 52 Week High Date09/01/21
  • 52 Week Low1.85
  • 52 Week Low Date06/16/22
  • Market Cap447.26M
  • Shares Out62.73M
  • 10 Day Average Volume0.84M
  • Dividend-
  • Dividend Yield-
  • Beta1.16
  • YTD % Change10.89

RATIOS/PROFITABILITY

  • EPS (TTM)-3.00
  • P/E (TTM)-2.38
  • Fwd P/E (NTM)-3.15
  • EBITDA (TTM)-168.769M
  • ROE (TTM)-
  • Revenue (TTM)-21.06M
  • Gross Margin (TTM)98.89%
  • Net Margin (TTM)-136.61%
  • Debt To Equity (MRQ)-961.28%

EVENTS

  • Earnings Date11/07/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Omeros Corp

There is no recent news for this security.

Profile

MORE
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject...
Gregory Demopulos M.D.
Chairman of the Board, President, Chief Executive Officer
Michael Jacobsen
Vice President - Finance, Chief Accounting Officer, Treasurer
Bruce Meiklejohn Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Peter Cancelmo J.D.
Vice President, General Counsel, Secretary
Tina Quinton J.D.
Vice President - Patents
Address
201 Elliott Avenue West
Seattle, WA
98119
United States

Top Peers

SYMBOLLASTCHG%CHG
ESPR
Esperion Therapeutics Inc
6.70+0.06+0.90%
AERI
Aerie Pharmaceuticals Inc
11.57+0.48+4.33%
OCUL
Ocular Therapeutix Inc
5.48+0.02+0.37%
OPTN
OptiNose Inc
3.76+0.17+4.74%
EYPT
EyePoint Pharmaceuticals Inc
11.11+0.02+0.18%